| ASSET | YEAR | % RETURN |
|---|---|---|
Halozyme Therapeutics (HALO) | 2004 | -41.33% |
Halozyme Therapeutics (HALO) | 2005 | -13.33% |
Halozyme Therapeutics (HALO) | 2006 | 342.31% |
Halozyme Therapeutics (HALO) | 2007 | -10.11% |
Halozyme Therapeutics (HALO) | 2008 | -20.79% |
Halozyme Therapeutics (HALO) | 2009 | 4.82% |
Halozyme Therapeutics (HALO) | 2010 | 33.56% |
Halozyme Therapeutics (HALO) | 2011 | 18.88% |
Halozyme Therapeutics (HALO) | 2012 | -31.04% |
Halozyme Therapeutics (HALO) | 2013 | 115.06% |
Halozyme Therapeutics (HALO) | 2014 | -35.45% |
Halozyme Therapeutics (HALO) | 2015 | 77.38% |
Halozyme Therapeutics (HALO) | 2016 | -41.64% |
Halozyme Therapeutics (HALO) | 2017 | 100.79% |
Halozyme Therapeutics (HALO) | 2018 | -28.63% |
Halozyme Therapeutics (HALO) | 2019 | 23.04% |
Halozyme Therapeutics (HALO) | 2020 | 139.54% |
Halozyme Therapeutics (HALO) | 2021 | -6.49% |
Halozyme Therapeutics (HALO) | 2022 | 42.96% |
Halozyme Therapeutics (HALO) | 2023 | -35.15% |
Halozyme Therapeutics (HALO) | 2024 | 29.81% |
Halozyme Therapeutics (HALO) | 2025 | 28.99% |
